Develop of Adolscenta
Essay Preview: Develop of Adolscenta
Report this essay
Field Research LaBretta Gregory July 13, 2015 PSYCH/600 Deborah Wilkerson This research paper will discuss how Strattera product claim to enhance, and how the publishedLiterature say about the issues or concerns of Strattera. It will also discuss what the research willreveal about how the promote a healthy development in this area, and the benefits of the product.It will also, show evidence to support this claim. Strattera is a non-stimulant medication, and Strattera is also a non-stimulant medication for treatment of distractibility, impulsivity, and hyperactivity in children, teens, with ADHD/ADD. According to Larry Silver M.D., states that Strattera was advertised as the first non-stimulant medication for ADHD/ADD, but there are several non-stimulant medication for ADHD/ADD such as tri-cyclic antidepressants, which is also prescribe to treat attention-deficit/hyperactivitydisorder. Strattera is approved for children aged 6 years and older, and the safety and the effectiveness has not been established in patients less than six years of age (Larry Silver M.D. 2011). According to Food and Drug Administration (FDA), issue today is issuing a Public Health Advisory to alert the physicians of the reports of suicidal thinking in children who have beenassociated with taking Strattera, which is a approved drug to treat children with ADHD. According to the FDA, they directed Eli Lilly & Company, and the manufacturer of Strattera
to develop a Medication Guide for patient’s and caregivers. Food and Drug Administration is also advising the health care providers and care givers of the children and adolescents being treated with Strattera should be monitored closely for worsening, agitation, irritability, and have suicidal thinking or behavior problems, during the first few months of therapy or when theirdoses are changed. According to Dr. Steven Galson, for the “Center for Drug Evaluation and Research, FDA,states that it has been one suicidal attempt by a patient who was taking Strattera, among the 2,200 patients in the trail. FDA have requested the manufacturer of Strattera to conduct theirDatabase of their clinical trail’s, which includes 2,200 patients, and 1,250 patients receivedStrattera, and 851 patients received placebo. After running their database it showed only 0.4%children were treated with Strattera, and reported suicidal thinking that compared to no casesin children with placebo. Strattera have been on the market since 2002, and have been used bymore than two million patients (FDA, 2005). Research may use music to promote a healthy development in this area. Research think usingmusic will promote the knowledge on how participants may use in this new area of technologyto learn about new materials and practice methods. Research reveals that music is a motivationaldevice for relaxing our bodies, it release stress or aggression. Researchers implementation in the future health promotion and rehabilitation programs should strengthen their focus on the musical,cultural, and physical activity on an individual level (Kari Batt-Rawden. 2005).